EP1368024A4 - TREATMENT OF RESTENOSIS - Google Patents

TREATMENT OF RESTENOSIS

Info

Publication number: EP1368024A4
Authority: EP; European Patent Office
Prior art keywords: restenosis; treatment
Prior art date: 2001-03-16
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP02707999A

Other languages

German (de)

French (fr)

Other versions

EP1368024A1 (en

Inventor

Alan Husband

Graham Edmund Kelly

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Marshall Edwards Inc

Original Assignee

Novogen Research Pty Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-16

Filing date

2002-03-15

Publication date

2009-03-18

2001-03-16 Priority claimed from AUPR3770A external-priority patent/AUPR377001A0/en

2001-06-26 Priority claimed from AUPR5926A external-priority patent/AUPR592601A0/en

2002-03-15 Application filed by Novogen Research Pty Ltd filed Critical Novogen Research Pty Ltd

2003-12-10 Publication of EP1368024A1 publication Critical patent/EP1368024A1/en

2009-03-18 Publication of EP1368024A4 publication Critical patent/EP1368024A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrane Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP02707999A 2001-03-16 2002-03-15 TREATMENT OF RESTENOSIS Withdrawn EP1368024A4 (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
AUPR3770A AUPR377001A0 (en)	2001-03-16	2001-03-16	Treatment of restenosis
AUPR377001		2001-03-16
AUPR5926A AUPR592601A0 (en)	2001-06-26	2001-06-26	Treatment of restenosis
AUPR592601		2001-06-26
PCT/AU2002/000288 WO2002074307A1 (en)	2001-03-16	2002-03-15	Treatment of restenosis

Publications (2)

Publication Number	Publication Date
EP1368024A1 EP1368024A1 (en)	2003-12-10
EP1368024A4 true EP1368024A4 (en)	2009-03-18

Family

ID=25646619

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP02707999A Withdrawn EP1368024A4 (en)	2001-03-16	2002-03-15	TREATMENT OF RESTENOSIS

Country Status (3)

Country	Link
EP (1)	EP1368024A4 (en)
JP (2)	JP4256679B2 (en)
WO (1)	WO2002074307A1 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPR363301A0 (en)	2001-03-08	2001-04-05	Novogen Research Pty Ltd	Dimeric isoflavones
US7338971B2 (en) *	2001-08-30	2008-03-04	El-Naggar Mawaheb M	Treatment of inflammatory, cancer, and thrombosis disorders
AUPR846401A0 (en) *	2001-10-25	2001-11-15	Novogen Research Pty Ltd	6-Hydroxy isoflavones, derivatives and medicaments involving same
MXPA04009896A (en) *	2002-04-09	2005-06-17	Novogen Res Pty Ltd	Therapeutic methods and compositions involving isoflav-3-ene and isoflavan structures.
US20090131513A1 (en) *	2005-03-24	2009-05-21	Novogen Research Pty Ltd.	Anti-inflammatory modalities
CA2617728A1 (en) *	2005-07-15	2007-01-25	Sahajanand Biotech Private Limited	Implantable medical devices comprising a flavonoid or derivative thereof for prevention of restenosis
CN101365446B (en) *	2005-07-29	2013-05-22	雷斯弗洛吉克斯公司	Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery via implantable medical devices
DK2118074T3 (en)	2007-02-01	2014-03-10	Resverlogix Corp	Compounds for the prevention and treatment of cardiovascular diseases
TWI366565B (en)	2007-06-06	2012-06-21	Otsuka Pharma Co Ltd	Quinolone compound and pharmaceutical composition
ES2532402T3 (en)	2008-06-26	2015-03-26	Resverlogix Corporation	Methods of preparing quinazolinone derivatives
CN102596196A (en) *	2008-10-22	2012-07-18	诺沃根研究控股有限公司	Method for inducing programmed cell death
TWI492943B (en)	2008-12-05	2015-07-21	大塚製藥股份有限公司	Quinolone compound and pharmaceutical composition
JP5635535B2 (en)	2009-01-08	2014-12-03	レスバーロジックスコーポレイション	Compounds for the prevention and treatment of cardiovascular disease
CN105859639A (en)	2009-03-18	2016-08-17	雷斯韦洛吉克斯公司	Novel anti-inflammatory agents
CN107252429B (en)	2009-04-22	2023-06-16	雷斯韦洛吉克斯公司	Novel anti-inflammatory agent
JP5992049B2 (en)	2011-11-01	2016-09-14	レスバーロジックスコーポレイション	Oral immediate release formulations for substituted quinazolinones
WO2014080291A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Biaryl derivatives as bromodomain inhibitors
WO2014080290A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en)	2012-12-21	2019-01-17	Zenith Epigenetics Ltd.	Novel heterocyclic compounds as bromodomain inhibitors
SG11201604490SA (en)	2014-02-07	2016-07-28	Novogen ltd	Functionalised benzopyran compounds and use thereof
CN114984016A (en)	2015-03-13	2022-09-02	雷斯韦洛吉克斯公司	Compositions and methods for treating complement-associated diseases
KR102005237B1 (en) *	2017-02-28	2019-07-30	서울대학교산학협력단	Recombinant e.coli producing equol derivatives and method for producing equol derivatives using thereof
CN119954787A (en)	2018-04-18	2025-05-09	星座制药公司	Regulators of methyl modification enzymes, compositions and uses thereof
US11919912B2 (en)	2018-05-21	2024-03-05	Constellation Pharmaceuticals, Inc.	Modulators of methyl modifying enzymes, compositions and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2190411A1 (en) *	1972-06-27	1974-02-01	Blaise Rolland	Derivs of 7-hydroxy isoflavones - vascular protectors, antiphlogistics and anti-allergics, prepd from a halocarboxylic acid and a 7-hydroxy isoflavone
WO1996031206A2 (en) *	1995-04-07	1996-10-10	Warner-Lambert Company	Flavones and coumarins as agents for the treatment of atherosclerosis
US5855892A (en) *	1997-09-19	1999-01-05	Potter; Susan M.	Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
WO2000030665A1 (en) *	1998-11-25	2000-06-02	Nutri Pharma Asa	Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
WO2001017986A1 (en) *	1999-09-06	2001-03-15	Novogen Research Pty Ltd	Compositions and therapeutic methods involving isoflavones and analogues thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AUPO203996A0 (en) *	1996-08-30	1996-09-26	Novogen Research Pty Ltd	Therapeutic uses
AU5440799A (en) *	1998-09-17	2000-04-10	Guido Schnyder	Method and drug for the treatment of coronary heart disease and for the prevention of restenosis after percutaneous transluminal coronary angioplasty
US6413546B1 (en) *	1999-03-18	2002-07-02	Indena, S.P.A.	Tablets incorporating isoflavone plant extracts and methods of manufacturing them
AUPQ008399A0 (en) *	1999-04-28	1999-05-27	Novogen Research Pty Ltd	Cariovascular applications
AUPQ008299A0 (en) *	1999-04-30	1999-05-27	G.J. Consultants Pty Ltd	Isoflavone metabolites

2002
- 2002-03-15 JP JP2002573014A patent/JP4256679B2/en not_active Expired - Fee Related
- 2002-03-15 EP EP02707999A patent/EP1368024A4/en not_active Withdrawn
- 2002-03-15 WO PCT/AU2002/000288 patent/WO2002074307A1/en not_active Ceased
2008
- 2008-12-05 JP JP2008311048A patent/JP2009143908A/en active Pending

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2190411A1 (en) *	1972-06-27	1974-02-01	Blaise Rolland	Derivs of 7-hydroxy isoflavones - vascular protectors, antiphlogistics and anti-allergics, prepd from a halocarboxylic acid and a 7-hydroxy isoflavone
WO1996031206A2 (en) *	1995-04-07	1996-10-10	Warner-Lambert Company	Flavones and coumarins as agents for the treatment of atherosclerosis
US5855892A (en) *	1997-09-19	1999-01-05	Potter; Susan M.	Method for decreasing LDL-cholesterol concentration and increasing HDL-cholesterol concentration in the blood to reduce the risk of atherosclerosis and vascular disease
WO2000030665A1 (en) *	1998-11-25	2000-06-02	Nutri Pharma Asa	Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases
WO2001017986A1 (en) *	1999-09-06	2001-03-15	Novogen Research Pty Ltd	Compositions and therapeutic methods involving isoflavones and analogues thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HUANG HUEI-CHEN ET AL: "Antiproliferative effect of baicalein, a flavonoid from a Chinese herb, on vascular smooth muscle cell", EUROPEAN JOURNAL OF PHARMACOLOGY, ELSEVIER BV, NL, vol. 251, no. 1, 1 January 1994 (1994-01-01), pages 91 - 93, XP002349489, ISSN: 0014-2999 *
See also references of WO02074307A1 *
TRAXLER P ET AL: "STRATEGIES TOWARD THE DESIGN OF NOVEL AND SELECTIVE PROTEIN TYROSINE KINASE INHIBITORS", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 82, no. 2/03, 10 June 1999 (1999-06-10), pages 195 - 206, XP000985237, ISSN: 0163-7258 *
TRIEU V N ET AL: "EGF-GENISTEIN INHIBITS NEOINTIMAL HYPERPLASIA AFTER VASCULAR INJURY IN A EXPERIMENTAL RESTENOSIS MODEL", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, NEW YORK, NY, vol. 35, no. 4, 1 April 2000 (2000-04-01), pages 595 - 605, XP001011807, ISSN: 0160-2446 *

Also Published As

Publication number	Publication date
WO2002074307A1 (en)	2002-09-26
JP4256679B2 (en)	2009-04-22
JP2004529907A (en)	2004-09-30
EP1368024A1 (en)	2003-12-10
JP2009143908A (en)	2009-07-02

Publication	Publication Date	Title
EP1368024A4 (en)	2009-03-18	TREATMENT OF RESTENOSIS
DE60236093D1 (en)	2010-06-02	REMOVABLE STENT
DK1944322T3 (en)	2015-06-22	Treatment of TNFalfa-related diseases
FR15C0028I2 (en)	2015-11-13	MANUFACTURE OF TIACUMICIN
DE50112209D1 (en)	2007-04-26	stent
EP1567101A4 (en)	2009-06-03	METHODS OF PROPHYLACTIC TREATMENT
BR0205514B1 (en)	2013-10-01	hair treatment processes
FIU20060389U0 (en)	2006-09-22	Treatment of bone diseases
DE60214255D1 (en)	2006-10-12	final piece
EP1485109A4 (en)	2009-07-29	VASCULAR TREATMENT
DE60208982D1 (en)	2006-04-13	footbath
EP1461027A4 (en)	2005-09-07	TREATMENT OF NEOPLASIA
MA26341A1 (en)	2004-10-01	STENTS
DE60227963D1 (en)	2008-09-11	TREATMENT SYSTEM
NO20041968L (en)	2004-05-11	Use of cystationin
EP1389105A4 (en)	2005-08-17	METHOD OF TREATMENT
EP1401377A4 (en)	2004-06-30	CANCER TREATMENT METHODS
ATE374011T1 (en)	2007-10-15	SKIN TREATMENT PRODUCTS
SE0301854L (en)	2003-08-26	Anti-corrosion treatment
DE50113918D1 (en)	2008-06-12	Quengel orthosis
EP1401494A4 (en)	2005-02-23	ANTI-TUMOR TREATMENT
IL144949A0 (en)	2002-06-30	Treatment of prion diseases with dmso
ATE333439T1 (en)	2006-08-15	PLANT TREATMENT PLANT
FR2825893B3 (en)	2003-09-12	TREATMENT TUNNEL
ITMI20011820A0 (en)	2001-08-28	TREATMENT OF BURNS

Legal Events

Date	Code	Title	Description
2003-10-24	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2003-12-10	17P	Request for examination filed	Effective date: 20030911
2003-12-10	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
2003-12-10	AX	Request for extension of the european patent	Extension state: AL LT LV MK RO SI
2009-03-18	A4	Supplementary search report drawn up and despatched	Effective date: 20090213
2009-12-23	17Q	First examination report despatched	Effective date: 20091120
2012-01-25	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: MARSHALL EDWARDS, INC.
2012-09-07	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2012-10-10	18D	Application deemed to be withdrawn	Effective date: 20120308